Archive

Latest KFF Health News Stories

Facing Headwinds on New Alzheimer’s Drug, Biogen Launches Controversial Campaign

KFF Health News Original

The makers of Aduhelm, a drug approved last month despite concerns raised by experts about its effectiveness, have launched a website and ads designed to urge people who are worried about their memory to ask doctors about testing. But some health advocates say it is misleading because some memory loss with aging is normal.

After 18 Months, Sutter Antitrust Settlement Finally Poised for Formal Approval

KFF Health News Original

A year and a half after Sutter Health agreed to a tentative settlement in a closely watched antitrust case, the San Francisco judge presiding over the case indicated she would sign off on the terms, pending agreement on another contentious issue: attorney fees.

KHN’s ‘What the Health?’: Delta Changes the Covid Conversation

KFF Health News Original

With covid cases on the upswing again around the country, partisan division remains over how to address the pandemic. Meanwhile, the Biden administration proposes bigger penalties for hospitals that fail to make their prices public as required. Stephanie Armour of The Wall Street Journal, Alice Miranda Ollstein of Politico and Tami Luhby of CNN join KHN’s Julie Rovner to discuss these issues and more. Also, for “extra credit,” the panelists suggest their favorite stories of the week they think you should read, too.

Big Leagues Balk at Endorsing Vaccination

KFF Health News Original

The major sports leagues are struggling to vaccinate enough of their players to protect the clubhouse and locker room, and few stars have stepped forward to pitch vaccination to teammates or fans. WNBA players are an exception, with a 99% vaccination rate and high-profile ads urging the public to get vaccinated.

Analysis: Necessary or Not, Covid Booster Shots Are Probably on the Horizon

KFF Health News Original

In today’s pharmaceutical universe, a simple “safe and effective” determination by the Food and Drug Administration to approve a drug can be manipulated to sell products of questionable value. And drugmakers can profit handsomely.

Though Millions Are at Risk for Diabetes, Medicare Struggles to Expand Prevention Program

KFF Health News Original

Medicare has proposed revamping its payment rules to get more people into a diabetes prevention plan that helps them eat better, exercise more and maintain a healthier lifestyle. Out of an estimated 16 million Medicare beneficiaries whose excess weight and other risk factors make them eligible, only 3,600 have participated since 2018.

California facilita que residentes de bajos ingresos obtengan y mantengan una cobertura de salud gratuita

KFF Health News Original

El acuerdo sobre el presupuesto estatal para 2021-22 incluye varias disposiciones que facilitarán el acceso y la permanencia en Medi-Cal. Todas las personas mayores de 50 años serán elegibles, independientemente de su estatus migratorio.

With a Diagnosis at Last, Black Women with ADHD Start Healing

KFF Health News Original

Black women and girls with attention deficit hyperactivity disorder often remain undiagnosed because their symptoms are mischaracterized by the blinders of sexism and racism. Getting treatment and finding the right medication can be even more difficult because they aren’t taken seriously or, worse, they’re racially profiled while getting their medicines.

California Makes It Easier for Low-Income Residents to Get and Keep Free Health Coverage

KFF Health News Original

State lawmakers aim to expand Medicaid enrollment by dedicating billions of dollars in coming years to simplifying paperwork, extending pregnancy coverage and opening the program to thousands of new enrollees, including older unauthorized immigrants and people who need nursing home care.

Sen. Wyden: $3.5T Budget May Have to Trim but It Can Set a Path to ‘Ambitious Goals’

KFF Health News Original

Sen. Ron Wyden (D-Ore.), who is helping to negotiate the health care spending framework for the Democrats’ budget plan, said lawmakers may have to settle for very basic versions of programs deployed in the package. But the key, he added, is to get the “architecture of these changes, bold changes,” started and show people what is possible.

Novavax’s Effort to Vaccinate the World, From Zero to Not Quite Warp Speed

KFF Health News Original

Novavax is a vaccine company that, despite $2 billion in new federal and international funding, still hasn’t come through with a licensed covid vaccine. It hopes it can still help to fight the global covid scourge, but will it deliver?